USA flag logo/image

An Official Website of the United States Government

ONCOGENE MARKERS AND CANCER RISK IN BENIGN BREAST CANCER

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
11127
Program Year/Program:
1989 / SBIR
Agency Tracking Number:
11127
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Grace Bio-oncology Laboratoryo
900 Auburn Road, Suite 105 Pontiac, MI 48342
View profile »
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1989
Title: ONCOGENE MARKERS AND CANCER RISK IN BENIGN BREAST CANCER
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

THIS RESEARCH WILL DEVELOP AN ASSAY TO PREDICT WHICH PATIENTS ARE AT HIGH RISK TO DEVELOP INVASIVE CANCER AT THE TIME OF BIOPSY-PROVEN BENIGN BREAST DISEASE. THE APPROACH WILL QUANTITATE CELLS IN BENIGN BREAST DISEASE TISSUE THAT HAVE ACQUIRED AUTONOMOUS PHENOTYPES WITH RESPECT TO HORMONES AND GROWTH FACTORS THAT NORMALLY EVOKE AN ORDERLY PATTERN OF GROWTH TO TERMINAL DIFFERENTIATION. SUCH AN APPROACH WILL IDENTIFY THE PRESENCE OF OCCULT AGGRESSIVE CANCER CLONES AND DETERMINE IF A HIGH DEGREE OF IMMORTALITY HAS BEEN ACQUIRED BY THE BENIGN LINEAGE. PHASE I RESEARCH WILL DETERMINE IF IT IS POSSIBLE TO DETECT BY IN SITU HYBRIDIZATION DIFFERENCES IN THE CELLULAR MRNA LEVEL OF EGF RECEPTOR (ERB-B), THYROXIN RECEPTOR (ERB-A), INSULIN, IGF-1 (SOMMA-TOMEDIN), ESTROGEN, PROGESTERONE, GLUCOCORTICOID OR PROLACTIN RECEPTOR, HER2/NEU, C-MYC,C-FOS, AND C-HA-RAS GENES SPECIFICALLY IN BENIGN BREAST DISEASE FROM PATIENTS WITH THE HIGHEST CANCER RISK (THOSE WITH INVASIVE CANCER INVOLVEMENT). IF THIS APPROACH IS VALID, IT IS EXPECTED TO SEE ONE OR MORE RECEPTORS OR C-ONC MRNA DIFFERENTIALLY OVER- OR UNDEREXPRESSED SPECIFICALLY IN ATYPICAL PROLIFERATIVE HYPERPLASIAS AND THE DIFFERENTIAL EXPRESSION SELECTED IN IN SITU LESIONS AND THE INVASIVE CANCERS FROM THE SAME PATIENTS. IN PHASE II, THE VALIDATED PROBE(S) WILL BE USED IN A STUDY OF MORE THAN 1,000 CANCER PATIENTS.

Principal Investigator:


0

Business Contact:

Small Business Information at Submission:

Grace Bio-oncology Laboratory
4170 Krafft Rd Port Huron, MI 48060

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No